SOURCE: PharmaRoth Labs, Inc.

September 22, 2015 08:30 ET

PharmaRoth Labs Announces Follow-On Order From International Pharmacy Retailer

Company Receives Additional $80,000 Order From Mexican Distributor

LAS VEGAS, NV--(Marketwired - Sep 22, 2015) - PharmaRoth Labs, Inc. (OTC PINK: ROTH) the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that the Company has received an additional order from its Mexican distributor, Marcas de Renombre. The order amount is for $80,000, which is in additional to the $80,000 order that was previously announced, placing Sucanon® on shelves at Farmacias de Similares, a large retailer with over 5,000 stores throughout Mexico, Guatamala, and Chile.

"We are extremely excited to announce a follow-on order of this size so soon after the initial order," stated Luis Lopez, CEO of PharmaRoth. "The fact that a Company with an international presence such as Similares recognizes the need for our product is a strong indication of our growth potential. We anticipate a very strong relationship with Similares."

For more information regarding Farmacias de Similares, please visit: www.farmaciasdesimilares.com.mx/ui/buscador/empresa.aspx

About Sucanon®

Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.

For more information regarding Sucanon®, please visit www.pharmaroth.com

About PharmaRoth

PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.

Contact Information

  • For Investor Relations contact:

    Michael Irving
    Paramount Advisors, LLC
    (407) 878-5462
    mike@parvise.com